Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1 Results remain consistent across secondary endpoints, including distant disease-free survival, with a trend for improved overall survival*1 Safety is in line with previously reported results with generally low-grade symptomatic adverse events, reinforcing well-tolerated profile1 People diagnosed with stage II or III HR+/HER ...